SAN DIEGO, May 17, 2019 – ProSciento, Inc., a clinical research organization (CRO) exclusively focused on NASH, diabetes, obesity and related metabolic diseases, today announced the appointment of Helge Guenther to the role of Chief Information Officer (CIO). Mr. Guenther joins ProSciento from BIT Group, a medical device development and manufacturing company for the life sciences industry, where he served as Chief Executive Officer of the US division and CIO of BIT Group Global. As a member of the executive team, Mr. Guenther will lead ProSciento’s global information technology strategies, including infrastructure expansion and continued innovation for technology platforms.
“We are thrilled to have Helge join ProSciento’s executive leadership team as we continue to expand the company’s global infrastructure. Helge’s strengths as a leader and his experience managing global technology teams, as well as his understanding of the complexities of operations for a clinical environment, make him a clear choice to lead ProSciento’s IT operations,” said Marcus Hompesch, MD, ProSciento’s Chief Executive Officer and Chairman of the Board.
Mr. Guenther joins ProSciento with more than 20 years of experience managing IT operations in highly regulated environments, including adherence to ISO, FDA, patient privacy, and data security standards. Prior to joining ProSciento, Mr. Guenther served as CEO of BIT Group USA and CIO of BIT Group Global, where he oversaw the expansion and optimization of global IT operations. Before that, Mr. Guenther was IT Director at Quest Diagnostics, where he focused on implementing new business solutions in close collaboration with the company’s operations and R&D departments. Prior to his role at Quest Diagnostics, Mr. Guenther was Global Program Manager at Baxter Bioscience, where he oversaw the implementation of Enterprise Resource Planning and related business systems across the company’s locations globally. Mr. Guenther earned his MBA from the University of Duesseldorf, Germany.
About ProSciento, Inc.
ProSciento is a highly specialized clinical research organization (CRO) exclusively focused on NASH, diabetes, obesity and related metabolic diseases. ProSciento works with biopharma companies worldwide to support their outsourced clinical research needs with comprehensive and customized services for multinational, early development clinical trial programs. Founded in 2003, ProSciento has conducted more than 280 clinical projects for diabetes, NASH and obesity and supported the development of many approved metabolic drugs and devices on the market globally. For more information, please visit www.prosciento.com.
inquiries, please contact:
Senior Director, Corporate Communications, ProSciento, Inc.